Issue 27 of Multiple Myeloma Research Review Highlights include: Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome. Loss of...
Myeloma NZ
CRISPR Modified CAR T-Cells Bolster Immuno Oncology Arsena
CRISPR (pronounced “crisper”) and CAR T-cell therapy are genetic technologies that have generated continued excitement during the last several...
PVX-410 Vaccine May Delay Disease Progression of Smoldering Multiple Myeloma
Previous studies have suggested that the progression of SMM to symptomatic multiple myeloma (MM) may be mediated by the immune system; reinforcing...
Once-Weekly Carfilzomib Submitted for FDA Approval in Myeloma
FDA approval is being sought for a once-weekly dosing option of carfilzomib (Kyprolis) for use in combination with dexamethasone as a treatment for...
Immune Approaches Hold Great Promise in Myeloma, Expert Says
Over the past 5 years, several therapies have been developed that have proven to be effective for patients with multiple myeloma. The FDA has...
Patient/Caregiver Survey
Please take 10 minutes to complete this survey to help us put myeloma on New Zealand’s health agenda and help you to have the best lives possible....
Pediatric Guidelines for CAR T-Cell Therapy Help Nurses Recognize AEs Earlier
A year after the first CAR T-cell therapy was approved to treat pediatric patients with relapsed and/or refractory CD19-positive acute lymphoblastic...
Elotuzumab Triplet Granted Priority Review by FDA for Myeloma
A supplemental biologics license application (sBLA) for elotuzumab (Empliciti) has been granted a priority review by the FDA for use in combination...
New Research to Explore ‘On and Off’ Switch for CAR T-Cell Therapy
Researchers are working on an “on and off” switch to improve the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy and counter...
Dr. Madduri on Eligibility for CAR T-Cell Therapy in Myeloma
Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric...
Want to make better T-cell therapies? First, figure out how they work
These man-made cancer-fighting molecules are infinitely variable, like a set of Legos, each one constructed to allow a patient’s immune cells to...
First in-depth profile of CAR T-cell signals suggests how to improve immunotherapy
CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded...